Advertisement

Advertisement

ABOS Stock Latest News

Acumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price

Company AnnouncementsAcumen Pharmaceuticals Warns Investors: Unchanged 10-K Risk Factors Still Weigh on Valuation and Share Price

Acumen Pharmaceuticals Bets Big on Alzheimer’s Trials

PremiumCompany Announcements

Acumen Pharmaceuticals Bets Big on Alzheimer’s Trials

8d ago

Acumen Updates Q1 Results and Alzheimer’s Pipeline Progress

PremiumCompany Announcements

Acumen Updates Q1 Results and Alzheimer’s Pipeline Progress

9d ago

Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure

PremiumCompany Announcements

Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure

2M ago

Acumen files to sell 10.83M shares of common stock for holders

PremiumThe Fly

Acumen files to sell 10.83M shares of common stock for holders

2M ago

Options Volatility and Implied Earnings Moves Today, March 26, 2026

PremiumMarket NewsOptions Volatility and Implied Earnings Moves Today, March 26, 2026

2M ago

Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027

Company Announcements

Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027

2M ago

Is ABOS a Buy, Before Earnings?

Pre-Earnings

Is ABOS a Buy, Before Earnings?

2M ago

Acumen participates in a conference call with Cantor

PremiumThe Fly

Acumen participates in a conference call with Cantor

2M ago

Acumen announces new research findings at Alzheimer’s and Parkinson’s conference

PremiumThe Fly

Acumen announces new research findings at Alzheimer’s and Parkinson’s conference

2M ago

Maintaining Buy on Acumen (ABOS): EBD-Enabled Alzheimer’s Pipeline, Extended Runway, and Discounted Valuation Ahead of ALTITUDE-AD Readout

PremiumRatings

Maintaining Buy on Acumen (ABOS): EBD-Enabled Alzheimer’s Pipeline, Extended Runway, and Discounted Valuation Ahead of ALTITUDE-AD Readout

2M ago

Acumen Pharma: Differentiated Alzheimer’s Oligomer Antibody and BBB‑Shuttle Platform Support Buy Rating and Higher $8 Target

PremiumRatings

Acumen Pharma: Differentiated Alzheimer’s Oligomer Antibody and BBB‑Shuttle Platform Support Buy Rating and Higher $8 Target

2M ago

Acumen price target raised to $8 from $7 at BTIG

PremiumThe FlyAcumen price target raised to $8 from $7 at BTIG

2M ago

Acumen Raises Capital to Advance Enhanced Brain Delivery

Company Announcements

Acumen Raises Capital to Advance Enhanced Brain Delivery

2M ago

Acumen announces $35.75M private placement

The Fly

Acumen announces $35.75M private placement

2M ago

Acumen price target raised to $7 from $4 at BTIG

PremiumThe Fly

Acumen price target raised to $7 from $4 at BTIG

4M ago

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

PremiumStock Analysis & Ideas

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

4M ago

Acumen Updates Investor Presentation, Highlights 2026 Alzheimer’s Milestones

PremiumCompany Announcements

Acumen Updates Investor Presentation, Highlights 2026 Alzheimer’s Milestones

4M ago

Acumen initiated with a Buy at Lucid Capital

PremiumThe Fly

Acumen initiated with a Buy at Lucid Capital

5M ago

Acumen announces new research at CTAD on ACU193

PremiumThe FlyAcumen announces new research at CTAD on ACU193

6M ago

Acumen price target lowered to $8 from $9 at BofA

The Fly

Acumen price target lowered to $8 from $9 at BofA

6M ago

Acumen first participant dosed in OLE portion of Phase 2 ALTITUDE-AD trial

The Fly

Acumen first participant dosed in OLE portion of Phase 2 ALTITUDE-AD trial

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >